Aptose Biosciences Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $53.39 million
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Aptose Biosciences Inc had its IPO on 2014-10-23 under the ticker symbol APTO.
The company operates in the Healthcare sector and Biotechnology industry. Aptose Biosciences Inc has a staff strength of 41 employees.
Shares of Aptose Biosciences Inc opened at $0.58 at the start of the last trading session i.e. 2023-03-19.
The stocks traded within a range of $0.52 - $0.58, and closed at $0.53.
This is a -5.36% slip from the previous day's closing price.
A total volume of 134,300 shares were traded at the close of the day’s session.
In the last one week, shares of Aptose Biosciences Inc have slipped by -5.36%.
Aptose Biosciences Inc's Key Ratios
Aptose Biosciences Inc has a market cap of $53.39 million, indicating a price to book ratio of 1.2762 and a price to sales ratio of 0.
In the last 12-months Aptose Biosciences Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-56411000. The EBITDA ratio measures Aptose Biosciences Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Aptose Biosciences Inc’s operating margin was 0% while its return on assets stood at -45.83% with a return of equity of -82.88%.
In Q3, Aptose Biosciences Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Aptose Biosciences Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-0.59 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Aptose Biosciences Inc’s profitability.
Aptose Biosciences Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -0.0797. Its price to sales ratio in the trailing 12-months stood at 0.
Aptose Biosciences Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $57.05 million
- Total Liabilities
- $10.23 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Aptose Biosciences Inc ended 2023 with $57.05 million in total assets and $0 in total liabilities. Its intangible assets were valued at $57.05 million while shareholder equity stood at $46.81 million.
Aptose Biosciences Inc ended 2023 with $0 in deferred long-term liabilities, $10.23 million in other current liabilities, 437469000.00 in common stock, $-454330000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $27.99 million and cash and short-term investments were $55.39 million. The company’s total short-term debt was $270,000 while long-term debt stood at $0.
Aptose Biosciences Inc’s total current assets stands at $56.58 million while long-term investments were $0 and short-term investments were $27.40 million. Its net receivables were $0 compared to accounts payable of $2.42 million and inventory worth $0.
In 2023, Aptose Biosciences Inc's operating cash flow was $-5078000.00 while its capital expenditure stood at $0.
Comparatively, Aptose Biosciences Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Aptose Biosciences Inc stock is currently trading at $0.53 per share. It touched a 52-week high of $1.55 and a 52-week low of $1.55. Analysts tracking the stock have a 12-month average target price of $7.8.
Its 50-day moving average was $0.65 and 200-day moving average was $0.69 The short ratio stood at 0.78 indicating a short percent outstanding of 0%.
Around 271.6% of the company’s stock are held by insiders while 3068.9% are held by institutions.
Frequently Asked Questions About Aptose Biosciences Inc
Similar Industry Stocks (Biotechnology)
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, which is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin’s lymphomas, as well as AML and HR MDS; and APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. It has agreements with CrystalGenomics, Inc. and OHM Oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.